Cedars Sinai
K

Debate: GLP-RA Should Be First Line Therapy for Treatment of Obesity...NOT

By Cedars Sinai FEATURING Kulmeet Sandhu
By Cedars Sinai FEATURING Kulmeet Sandhu
1,519 views
June 4, 2024
6 Comments
Login to view comments. Click here to Login

Featured Video

48:22
Lilly Diabetes

A Journey Through Clinical Efficacy and Safety Data Comparing Two T2…

Feat. B. Hirsch

Featured Video

04:47
Novartis Cardiology

Examining MOA, Safety, and Efficacy Data for a Non-Statin Lipid-Lowe…

Related Content

AUTOPLAY
AdventHealth

Endobariatric Symposium and Suturing Masterclass 2024

Sun, Oct 6, 2024
64:45
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

Primer on Diabetes Management

Feat. S. Inzucchi
26:57
Houston Methodist

Endoscopic Weight Loss Therapies - A Paradigm Shift in the Treatment…

Feat. T. R. Mccarty
18:43
ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

Feat. R. DeFronzo
15:06
Robert Busch

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

12:26
Juan Frias

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

21:33
AdventHealth

FLOW: The First Dedicated CKD Outcomes Trial With a GLP-1 Receptor A…

Feat. R. Pratley
27:24
Cardiometabolic Health Congress (CMHC)

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Feat. L. Sloan
15:33
Ken Fujioka

Could GLP-1's be a 'Game Changer' For Weight Loss? Ca…

26:49
Diana Isaacs

Tirzepatide Updates

26:32
Practical Ways to Achieve Targets in Diabetes Care

Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity

Feat. S. Nissen
08:35
Susan Brian

Labs to Check on Semaglutide or Tirzepatide

20:24
Diana Isaacs

Tirzepatide for Type 2 Diabetes

07:41
Susan Brian

Weightloss in Menopause

06:31
Susan Brian

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

05:08
Susan Brian

The Differences Between the Products of GLP1's and GLP/GIPs

32:27
Scripps Health

Obesity: A Serious Cardiovascular Risk Factor? A Review of GLP-1 Rec…

Feat. L. Vincent
36:34
Scripps Health

GLP-1 Hysteria

Feat. S. Harris
14:03
Baylor College of Medicine

Creating the Ideal Comprehensive Bariatric Program

Feat. S. Mattar
49:21
McMaster University Department of Medicine

Semaglutide: Where Are We Now and Where Are We Going?

Feat. S. Boushahri, D. Lazzam, K. MacEachern
23:35
Canadian Collaborative Research Network

Is Obesity Management the Next Frontier?

Feat. A. Michael Lincoff